KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Other Operating Expenses (2016 - 2025)

AbbVie (ABBV) has disclosed Other Operating Expenses for 14 consecutive years, with $217.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 3000.0% to $217.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.6 billion, a 137214.29% increase, with the full-year FY2025 number at $241.0 million, up 3342.86% from a year prior.
  • Other Operating Expenses was $217.0 million for Q4 2025 at AbbVie, down from $5.1 billion in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $5.1 billion in Q2 2025 to a low of -$229.0 million in Q3 2022.
  • A 5-year average of $1.2 billion and a median of $170.5 million in 2022 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: crashed 145.8% in 2022, then skyrocketed 3000.0% in 2025.
  • AbbVie's Other Operating Expenses stood at $500.0 million in 2021, then plummeted by 99.8% to $1.0 million in 2022, then surged by 16800.0% to $169.0 million in 2023, then plummeted by 95.86% to $7.0 million in 2024, then surged by 3000.0% to $217.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Other Operating Expenses are $217.0 million (Q4 2025), $5.1 billion (Q2 2025), and $4.2 billion (Q1 2025).